JAMA (Journal of the American Medical Association)
Відкрити в Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Показати більше📈 Аналітичний огляд Telegram-каналу JAMA (Journal of the American Medical Association)
Канал JAMA (Journal of the American Medical Association) (@jamaupdates) у мовному сегменті Англійська є активним учасником. На даний момент спільнота об'єднує 16 626 підписників, посідаючи 1 481 місце в категорії Медицина та 2 252 місце у регіоні США.
📊 Показники аудиторії та динаміка
З моменту свого створення невідомо, проект продемонстрував стрімке зростання, зібравши аудиторію у 16 626 підписників.
За останніми даними від 11 жовтня, 2026, канал демонструє стабільну активність. Хоча за останні 30 днів спостерігається зміна кількості учасників на 281, а за останні 24 години на 0, загальне охоплення залишається високим.
- Статус верифікації: Не верифікований
- Рівень залученості (ER): Середній показник залученості аудиторії становить 3.90%. Протягом перших 24 годин після публікації контент зазвичай збирає 1.87% реакцій від загальної кількості підписників.
- Охоплення публікацій: В середньому кожен допис отримує 647 переглядів. Протягом першої доби публікація в середньому набирає 310 переглядів.
- Реакції та взаємодія: Аудиторія активно підтримує контент: середня кількість реакцій на один пост – 1.
- Тематичні інтереси: Контент зосереджений навколо ключових тем, таких як patient, disease, treatment, drug, guideline.
📝 Опис та контентна політика
Автор описує ресурс як майданчик для висловлення суб'єктивної думки:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Завдяки високій частоті оновлень (останні дані отримано 12 жовтня, 2026), канал підтримує актуальність та високий рівень охоплення публікацій. Аналітика показує, що аудиторія активно взаємодіє з контентом, що робить його важливою точкою впливу в категорії Медицина.
16 626
Підписники
Немає даних24 години
+627 днів
+28130 днів
Триває завантаження даних...
Схожі канали
Хмара тегів
Вхідні та вихідні згадування
---
---
---
---
---
---
Залучення підписників
жовтень '26жовт '26
жовтень '26
+90
в 0 каналах
вересень '26
+301
в 0 каналах
Get PRO
серпень '26
+361
в 0 каналах
Get PRO
липень '26
+440
в 0 каналах
Get PRO
червень '26
+422
в 1 каналах
Get PRO
травень '26
+584
в 0 каналах
Get PRO
квітень '26
+437
в 0 каналах
Get PRO
березень '26
+217
в 0 каналах
Get PRO
лютий '26
+247
в 0 каналах
Get PRO
січень '26
+321
в 0 каналах
Get PRO
грудень '25
+277
в 0 каналах
Get PRO
листопад '25
+366
в 2 каналах
Get PRO
жовтень '25
+164
в 0 каналах
Get PRO
вересень '25
+12
в 0 каналах
Get PRO
серпень '25
+29
в 0 каналах
Get PRO
липень '25
+30
в 0 каналах
Get PRO
червень '25
+17
в 0 каналах
Get PRO
травень '25
+9
в 0 каналах
Get PRO
квітень '25
+5
в 0 каналах
Get PRO
березень '25
+17
в 0 каналах
Get PRO
лютий '25
+12
в 0 каналах
Get PRO
січень '25
+18
в 1 каналах
Get PRO
грудень '24
+237
в 0 каналах
Get PRO
листопад '24
+1 122
в 0 каналах
Get PRO
жовтень '24
+1 120
в 0 каналах
Get PRO
вересень '24
+1 527
в 1 каналах
Get PRO
серпень '24
+1 128
в 1 каналах
Get PRO
липень '24
+1 216
в 0 каналах
Get PRO
червень '24
+781
в 1 каналах
Get PRO
травень '24
+797
в 1 каналах
Get PRO
квітень '24
+808
в 1 каналах
Get PRO
березень '24
+821
в 2 каналах
Get PRO
лютий '24
+753
в 1 каналах
Get PRO
січень '24
+768
в 0 каналах
Get PRO
грудень '23
+716
в 1 каналах
Get PRO
листопад '23
+96
в 1 каналах
Get PRO
жовтень '23
+86
в 0 каналах
Get PRO
вересень '23
+73
в 0 каналах
Get PRO
серпень '23
+90
в 0 каналах
Get PRO
липень '23
+107
в 0 каналах
Get PRO
червень '23
+105
в 0 каналах
Get PRO
травень '23
+169
в 0 каналах
Get PRO
квітень '23
+128
в 0 каналах
Get PRO
березень '23
+84
в 0 каналах
Get PRO
лютий '23
+75
в 0 каналах
Get PRO
січень '23
+71
в 0 каналах
Get PRO
грудень '22
+74
в 0 каналах
Get PRO
листопад '22
+149
в 0 каналах
Get PRO
жовтень '22
+90
в 0 каналах
Get PRO
вересень '22
+138
в 0 каналах
Get PRO
серпень '22
+77
в 0 каналах
Get PRO
липень '22
+50
в 0 каналах
Get PRO
червень '22
+96
в 0 каналах
Get PRO
травень '22
+75
в 0 каналах
Get PRO
квітень '22
+80
в 0 каналах
Get PRO
березень '22
+65
в 0 каналах
Get PRO
лютий '22
+26
в 0 каналах
Get PRO
січень '22
+56
в 0 каналах
Get PRO
грудень '21
+44
в 0 каналах
Get PRO
листопад '21
+39
в 0 каналах
Get PRO
жовтень '21
+61
в 0 каналах
Get PRO
вересень '21
+66
в 0 каналах
Get PRO
серпень '21
+65
в 0 каналах
Get PRO
липень '21
+96
в 0 каналах
Get PRO
червень '21
+120
в 0 каналах
Get PRO
травень '21
+130
в 0 каналах
Get PRO
квітень '21
+812
в 0 каналах
| Дата | Залучення підписників | Згадування | Канали | |
| 10 жовтня | +7 | |||
| 09 жовтня | +19 | |||
| 08 жовтня | +10 | |||
| 07 жовтня | +4 | |||
| 06 жовтня | +17 | |||
| 05 жовтня | +7 | |||
| 04 жовтня | +11 | |||
| 03 жовтня | +5 | |||
| 02 жовтня | +8 | |||
| 01 жовтня | +2 |
Дописи каналу
The Pitfalls of Buying Unapproved GLP-1 Drugs
https://jamanetwork.com/journals/jama/fullarticle/2855339
This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.
| 2 | As Drinking Declines, Cannabis Is on the Rise
https://jamanetwork.com/journals/jama/fullarticle/2855338
This Medical News article discusses the increase in routine cannabis use among younger adults, which corresponds with a decrease in regular alcohol use. | 530 |
| 3 | JAMA Editors' Summary Podcast October 9, 2026
https://jamanetwork.com/journals/jama/fullarticle/2855377
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA. | 510 |
| 4 | FDA Authorizes First Continuous Ketone Monitor for Diabetes
https://jamanetwork.com/journals/jama/fullarticle/2855345
The US Food and Drug Administration (FDA) authorized the first wearable device that continuously monitors ketone levels in people with type 1 diabetes. | 488 |
| 5 | Review on Adult Male Hypogonadism—Reply
https://jamanetwork.com/journals/jama/fullarticle/2855025
In Reply We appreciate the letter about our Review and are grateful for the opportunity to discuss the effects of exogenous testosterone on spermatogenesis and male fertility. | 629 |
| 6 | Review on Adult Male Hypogonadism
https://jamanetwork.com/journals/jama/fullarticle/2855027
To the Editor A recent review of adult male hypogonadism thoroughly discussed several important treatment-related adverse effects and safety considerations of testosterone use, including erythrocytosis, venous thromboembolic events, blood pressure elevation, and prostate-related monitoring. However, one clinically important adverse effect of testosterone therapy was overlooked: suppression of spermatogenesis and the subsequent risk of infertility in reproductive-aged men. | 594 |
| 7 | Survivors of Cyanotic Congenital Heart Disease
https://jamanetwork.com/journals/jama/fullarticle/2855028
To the Editor A recent Review provided a comprehensive discussion regarding long-term management of patients born with cyanotic congenital heart disease. As maternal-fetal medicine specialists, we would like to highlight the maternal and neonatal risks associated with both repaired and unrepaired cyanotic congenital heart disease in pregnancy and emphasize that all of these reproductive-aged patients should have pregnancy intentions routinely evaluated and be provided access to contraception, preconception, and multidisciplinary pregnancy care as appropriate. | 471 |
| 8 | Longitudinal Trends and Characteristics of Hospital Closures and Openings
https://jamanetwork.com/journals/jama/fullarticle/2855029
This study assesses hospital closures and openings from 2010-2025 to characterize net changes in hospitals and beds, factors associated with closures and openings, and changes in distance to the nearest hospital after closures. | 363 |
| 9 | Catching Up With the Propaganda for Health
https://jamanetwork.com/journals/jama/fullarticle/2855030
Any one who reads popular periodicals or follows the current trends in folk psychology and national habits of thought can readily discover the growing popular enthusiasm for the conservation of health. Obviously, all matters of health and disease are of foremost concern to the physician; in him rests the largest public obligation as well as personal necessity of keeping abreast not only of the discoveries that bear on diagnosis and treatment but also of the features somewhat indefinitely described as preventive medicine. Every professional organization to which he belongs is in some way identified with the program of modern public hygiene. | 380 |
| 10 | The Ethics of Germline Gene Editing, Revisited
https://jamanetwork.com/journals/jama/fullarticle/2855020
The ethics of germline gene editing are discussed in this Viewpoint regarding 3 applications: basic science, treatment and prevention, and enhancement. | 368 |
| 11 | Women’s Health in 2027—A Call for Papers
https://jamanetwork.com/journals/jama/fullarticle/2855130
What if we could shift the conversation about women’s health beyond the “usual” categories of reproductive health, pregnancy, menopause, and cancer (breast and gynecologic)? JAMA and the JAMA Network are committed to elevating women’s health across the full spectrum of health care across the globe. | 395 |
| 12 | Prevalence of Unrecognized and Recognized Myocardial Infarction
https://jamanetwork.com/journals/jamacardiology/fullarticle/2854801
This cohort study uses data from the Rotterdam Study to assess temporal trends in the prevalence of recognized and unrecognized MI over 3 epochs in the general worldwide population. | 446 |
| 13 | Cement Embolism After Vertebroplasty
https://jamanetwork.com/journals/jamacardiology/fullarticle/2854803
This case report discusses a diagnosis of intracardiac and pulmonary polymethyl methacrylate cement embolization in a man aged 45 years with a history of multiple myeloma and vertebroplasty. | 413 |
| 14 | Hypertension Management and Control in Cienfuegos, Cuba
https://jamanetwork.com/journals/jama/fullarticle/2854963
This population-based cross-sectional survey assesses hypertension prevalence and indicators of management and control in 2023 and compares these findings with a similar population-based survey conducted in 2011. | 540 |
| 15 | Facilitating Real-World Advance Care Planning
https://jamanetwork.com/journals/jama/fullarticle/2854964
Advance care planning (ACP) and serious illness communication guides complex medical care and is widely recommended in national guidelines, quality metrics, and Medicare policy, which has allowed physician reimbursement for ACP conversations since 2016. Yet prior research reveals disparities in serious illness care among Black individuals in the United States, and there is a paucity of research on the effectiveness of ACP interventions among them. Possible reasons for these disparities include, but are not limited to, inequitable access to health care and justifiable distrust in the health system. | 525 |
| 16 | Beyond the Trial—What Do Extension Studies Add to Randomized Clinical Trials?
https://jamanetwork.com/journals/jama/fullarticle/2854965
One critical shortcoming of many clinical therapeutic trials is their focus on short-term effects, leaving unanswered questions about how participants fare in the longer term. Trial extension studies are conducted to address this gap, allowing assessment of both durability of treatment benefit (eg, whether disease remission or improvements in function are maintained or diminished over time) and long-term safety (such as incidence of delayed adverse events). In therapeutic trials, extension studies can mitigate the ethical burden associated with discontinuation of potentially effective treatments or long-term administration of placebo or inferior interventions among those initially assigned to the control group. The prospect of an extension study may also give participants greater incentive to enroll in trials, despite concerns about being assigned to the control group in the initial phase of the research. Because extension studies build on existing trial infrastructure, they also allow additional and potentially valuable information to be derived from trials that already require significant up-front investment. | 469 |
| 17 | Multiple Violaceous-to-Brownish Patches and Plaques on the Trunk
https://jamanetwork.com/journals/jama/fullarticle/2854966
A patient with a history of lung adenocarcinoma had violaceous-to-brown cutaneous patches and plaques. Computed tomography showed splenomegaly and multicentric lymphadenopathy, and laboratory testing showed an elevated erythrocyte sedimentation rate and levels of IgG, IgG4, IgA, and interleukin 6. What is the diagnosis and what would you do next? | 359 |
| 18 | The Quiet Half of Good Medicine
https://jamanetwork.com/journals/jama/fullarticle/2854957
This Viewpoint discusses the need to discern when medical intervention is needed vs when supportive care and monitoring are appropriate. | 398 |
| 19 | Hypertension Control in Low- and Middle-Income Settings
https://jamanetwork.com/journals/jama/fullarticle/2855205
Hypertension control is among the most urgent and attainable priorities in global cardiovascular health. High blood pressure remains a leading cause of myocardial infarction, stroke, heart failure, chronic kidney disease, and dementia, yet it can be detected with a simple measurement and treated with effective, inexpensive medicines. The World Health Organization (WHO) estimates that 1.4 billion adults aged 30 to 79 years had hypertension in 2024 and that only 320 million, or 23%, had their blood pressure controlled. Ninety-nine countries had national control rates below 20%. The gap is widest in low- and middle-income countries (LMICs), where most people with hypertension live and health systems must address a large cardiovascular disease burden with limited resources. | 456 |
| 20 | Landmark Significance and Future Directions of the RAPID-TEST Trial
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2854545
To the Editor The RAPID-TEST trial by Hay et al represents to our knowledge the first pragmatic randomized clinical trial to evaluate the use of multiplex molecular point-of-care testing (POCT) for respiratory tract infections in primary care. It establishes a rigorous evidence benchmark for the field. At the same time, its design limitations and evidence gaps provide a critical roadmap for future advancement. | 646 |
